May 2006
Worldwide Biotech;May2006, Vol. 18 Issue 5, p5
Trade Publication
The article reports on the completion of the first stage of collaboration between SAFC Biosciences and Vivalis. Such completion was demonstrated with the launch of their EX-CELL� and EBx� viral growth and production media. Under the research and development agreement, SAFC Biosciences has developed and optimized media for the use with Vivalis' EBx cells in the commercial development of viral vaccines for clinical trials and recombinant protein production.


Related Articles

  • Cellular and Humoral Immune Responses to a Canarypox Vaccine Containing Human Immunodeficiency Virus Type 1 Env, Gag, and Pro in Combination with RGP120.  // Journal of Infectious Diseases;2/15/2001, Vol. 183 Issue 4, p563 

    Features a study on the combination vaccine regimen consisting of a canarypox (CP) vector containing env, gag and pro, in combination with a recombinant gp120 subunit protein. Disadvantages of recombinant vaccinia virus vaccines as a vector for an HIV-1 vaccine; Background of CP; Materials and...

  • NEWS IN BRIEF. Tyler, Alan // European Chemical News;2/16/2004, Vol. 80 Issue 2087, p22 

    Presents news briefs on the chemical industry in Europe as of February 22, 2004. Research and development expansion project in Singapore by Swiss flavours and fragrances specialist Givaudan; Increase in profits of Sigma-Alfrich.

  • RECOMBINANT BOVINE HERPESVIRUS-1 EXPRESSING p23 PROTEIN OF CRYPTOSPORIDIUM PARVUM INDUCES NEUTRALIZING ANTIBODIES IN RABBITS. Takashima, Yasuhiro; Xuan, Xuenan; Kimata, Isao; Iseki, Motohiro; Kodama, Yoshikatsu; Nagane, Noriko; Nagasawa, Hideyuki; Matsumoto, Yasunobu; Mikami, Takeshi; Otsuka, Haruki // Journal of Parasitology;Apr2003, Vol. 89 Issue 2, p276 

    Discusses the construction of a recombinant bovine herpesvirus-1 (BHV-1) expressing p23 protein as a candidate for a vaccine against cryptosporidiosis. Frequency of homologous recombination; Detection of the p23 protein expressed in vitro by recombinant BHV-1; Pathogenic and immunogenic...

  • Sigma-Aldrich set for global growth in pharmaceuticals and fine chemicals. Boswell, Clay // Chemical Market Reporter;08/03/98, Vol. 254 Issue 5, p17 

    Focuses on Sigma-Aldrich Corp.'s fine chemicals division. Expansions and upgrades of cGMP capacity; Renovation of Sigma Scotland's cell culture facility; Additions at Sigma's Saint Louis site; Drug master file filed by Sigma-Aldrich.

  • Sigma-Aldrich rated `buy'. Chang, Joseph // Chemical Market Reporter;02/09/98, Vol. 253 Issue 6, p19 

    Cites strong buy recommendations for Sigma-Aldrich Corp. due to higher demands for research chemicals, according to investment analysts.

  • Sigma launches website.  // Chemical Market Reporter;02/09/98, Vol. 253 Issue 6, p33 

    Announces the World Wide Web site of Sigma-Aldrich Fine Chemicals, a division of Sigma-Aldrich Corp. of Saint Louis, Missouri.

  • Sigma-Aldrich is starting contract cell culture unit.  // Chemical Market Reporter;08/11/97, Vol. 252 Issue 6, p3 

    Reports that Sigma-Aldrich Fine Chemicals, the bulk chemicals division of Sigma-Aldrich Inc. has initiated validation of a cyclic guanosine monophosphate facility dedicated to manufacturing cell culture products. Scheduled validation and audit tours for the unit; Capabilities of the plant.

  • Plant Viruses in Plant Molecular Pharming: Toward the Use of Enveloped Viruses. Ibrahim, Ahmad; Odon, Valerie; Kormelink, Richard // Frontiers in Plant Science;6/19/2019, pN.PAG 

    Plant molecular pharming has emerged as a reliable platform for recombinant protein expression providing a safe and low-cost alternative to bacterial and mammalian cells-based systems. Simultaneously, plant viruses have evolved from pathogens to molecular tools for recombinant protein...

  • Untitled.  // Chemical Market Reporter;11/10/97, Vol. 252 Issue 19, p3 

    Presents the cGMP facility of Sigma-Aldrich Corp. in Gillingham, United Kingdom. Function of the facility.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics